Ryutaro Nakashima

Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist

Rieko Takano, Masao Yoshida, Masahiro Inoue et al. · ACS Medicinal Chemistry Letters · 2015 · 33 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats

Taishi Yoshida, Akira Okuno, Jun Tanaka et al. · European Journal of Pharmacology · 2009 · 29 citations

Life Sciences, Endocrinology, Physiology +13

Potent Antidiabetic Effects of Rivoglitazone, a Novel Peroxisome Proliferator–Activated Receptor-γ Agonist, in Obese Diabetic Rodent Models

Shoichi Kanda, Ryutaro Nakashima, Kanako Takahashi et al. · Journal of Pharmacological Sciences · 2009 · 28 citations · Full text

Medicine, Endocrinology, Pharmacology +14

Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists

Rieko Takano, Masao Yoshida, Masahiro Inoue et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists

Ryutaro Nakashima, Tatsuya Yano, Junko Ogawa et al. · European Journal of Pharmacology · 2014 · 17 citations

Medicine, Endocrinology, Pharmacology +17